SPRO Spero Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SPRO

Price (delayed)

$2.2

Market cap

$127.38M

P/E Ratio

8.15

Dividend/share

N/A

EPS

$0.27

Enterprise value

$73.73M

?
Relative Growth: Rel. Growth: 65
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: 96
Relative Profitability: Rel. Profitability: 99

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Highlights
The net income has soared by 122% YoY and by 78% from the previous quarter
The EPS has surged by 121% year-on-year and by 80% since the previous quarter
The equity has soared by 57% year-on-year but it has declined by 10% since the previous quarter
SPRO's revenue is up by 37% YoY but it is down by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://sperotherapeutics.com
Peers: FC IBM DV

Key stats

What are the main financial stats of SPRO

SPRO stock price

How has the Spero Therapeutics stock price performed over time
Intraday
-0.9%
1 week
8.91%
1 month
-22.26%
1 year
-24.14%
YTD
-5.58%
QTD
-0.45%

Financial performance

How have Spero Therapeutics's revenue and profit performed over time
Revenue
$61.19M
Gross profit
$61.19M
Operating income
$13.51M
Net income
$15.24M
Gross margin
100%
Net margin
24.9%
SPRO's operating margin has surged by 133% since the previous quarter and by 113% year-on-year
The net income has soared by 122% YoY and by 78% from the previous quarter
Spero Therapeutics's operating income has soared by 118% YoY and by 114% from the previous quarter
The net margin has surged by 116% year-on-year and by 95% since the previous quarter

Price vs fundamentals

How does SPRO's price correlate with its fundamentals

Growth

What is Spero Therapeutics's growth rate over time

Valuation

What is Spero Therapeutics stock price valuation
SPRO P/E details
P/E
8.15
P/B
2.41
P/S
2.06
EV/EBIT
4.76
EV/EBITDA
4.76
EV/Sales
1.2
The EPS has surged by 121% year-on-year and by 80% since the previous quarter
The equity has soared by 57% year-on-year but it has declined by 10% since the previous quarter
The price to book (P/B) is 29% less than the last 4 quarters average of 3.4 but 4.8% more than the 5-year quarterly average of 2.3
SPRO's P/S is 66% below its 5-year quarterly average of 6.0 and 18% below its last 4 quarters average of 2.5
SPRO's revenue is up by 37% YoY but it is down by 8% from the previous quarter

Efficiency

How efficient is Spero Therapeutics business performance
SPRO's ROIC has soared by 145% YoY and by 93% QoQ
The return on assets has surged by 142% year-on-year and by 92% since the previous quarter
Spero Therapeutics's ROE has soared by 129% YoY and by 58% from the previous quarter
The return on sales has surged by 116% year-on-year and by 92% since the previous quarter

Dividends

What is SPRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRO.

Financial health

How did Spero Therapeutics financials performed over time
SPRO's total liabilities has dropped by 86% year-on-year and by 39% since the previous quarter
The current ratio has grown by 38% from the previous quarter
The debt is 95% smaller than the equity
The debt to equity has plunged by 58% YoY
The equity has soared by 57% year-on-year but it has declined by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.